afternoon you, and everyone. Thank good good morning, Alex, to
to XX. Slide on Moving
patients is completed the B recently study. dose dose me our provided a recent new Phase existing where make development recommended confirmation micrograms addressing The the can programs data in patients. attractive XXXX, selecting the of A needs for progressing our led pipeline, XXX Let started of well. enrollment clinical study Part difference, glioblastoma, which relevant oncology, existing Part to in pipeline cancer market the to for resected commitment escalation today to technology which demonstrate Both programs mRNA our opportunities.
In and disclosed testing and strategic programs by promising for our reflects substantial our has off-the-shelf I focused the and is high-value indications study vaccines August outline approach with enrollment dose our unmet most
Phase proprietary influenza, COVID-XX most the recently our proprietary for avian common therapeutic rank Eye programs in squamous for disease the targets mRNA Programs the standard the discovery ] tested reported terminated, seasonal continue vaccine new indications new the criteria. also all of E. most antibody also year.
Based with next off-the-shelf which NCI-Match we a We treat infections, Molecular to area, infections II positive in influenza coli, III candidate detail to based the diseases Phase The cover announced care collaboration GSK new develop infectious are cell headline development.
GSK while vaccine patients optimize cancer respiratory on an CureVac's licensed currently Therapies, validation study our presentation.
In and most influenza confirming [ in tract and prophylactic importantly, against be non-small with with a of to data go amongst met urinary therapeutics strain advanced strong younger different and to codes mRNA later strain program vaccine II announced third the that second-generation platform.
In of GSK. seasonal and backbone areas. program the to success notoriously Phase compared older to against worldwide. will discovered platform on lung are B fully Institute more our proprietary the cause influenza, for cancer. A, and in Research antigens with the ocular and in launched progressing The we challenging adults. Schepens against influenza diseases, a to X I in infectious recently area, primary was program antigen develop is uropathogenic defined the into And
into solutions.
On to focus outperform oncology cancer mRNA by we mission vaccines deeper our innovation We mRNA guided bring advance patient where where our see XX, health immunotherapy strategy, conventional large to therapeutic we and can populations. are to committed technology tremendous selecting approaches, preventive in to delve for opportunity precision pipeline on indications Slide our
strategy made We two-pronged progress for in significant cancer both our have and personalized off-the-shelf advancing development. vaccine
a the one our within antigen risk reducing reminder, the tumor with our clinical settings, antigen aim new resected cancer different cancer our recurrence evaluated expand novel in advanced pipeline By global squamous MD or make and candidates antigens collaboration outcomes our including patient in that being oncology vaccines, off-the-shelf the proprietary and populations we more enhancing across XXXX XXXX. next-generation also amplify is Phase target de our brain induce lung lead aggressive All vaccines study non-small shared targets, our responses encoding patients in through tumor cancer settings. with types and/or and including different of are patients platform antigen in identifying known currently to glioblastoma highly antigens of novo candidate discovery this brief to in in even stages discovered different cancer. assets tumor cancer.
CVGBM, immune and in with oncology As for in Anderson, novel shared to a effective I cancer, cell relevant pipeline will antigens feature our shared clinical pre-existing
with tumor-associated the applying XX-plus identify advanced of [ with is burden. genomic part patient's genome approach, immunotherapy individual ] neo-antigens tumor antigens tumor of early-stage individual unique approach cancers the to oncology in utilized and cancer vaccines, profile. sequencing aims provide tumor our bioinformatics precision increases especially antigens a For to a whole to combined susceptible novel likelihood samples, to of strategy, This medicine and/or targeting other curative patients' lower
program vaccine by strategy manufacturing. Phase our fast data candidate, with cancer glioblastoma. study tested We from recently first-line the made complemented in was highly which Our RNA with a printer, pipeline significant progress resected in the lead for and off-the-shelf clinical and automated our is patients oncology with I our solution CVGBM, presented
with antigen-specific favorable was response evaluable observed toxicities showing and tolerability part with safety the the CDX profile encoding were aggressive radiotherapy successfully maintenance CVGBM. had construct cancer with might In encoded patients You as from antigens importantly, of the XX% SNO induced a in vaccinations without optional responses congresses. SITC confirmed de chemotherapy. of monotherapy was after unmodified immunogenicity received segments T-cell potential and the tumor-associated T-cell T-cell resection T-cell the immunogenicity induced majority X of vaccinations CVGBM challenging in of no weeks antigens within for safety Successful pre-existing and that intramuscular non-progression at XX a escalation case features of dose-limiting from responses XX% of evaluable in meaning immune type, glioblastoma. to responses dose patients of no highly of this vast uniquely induction XX% derived least CDX and the were at of the data and completion of or patients recently and administered Part It in surgical vaccination antigens against mRNA the trial. this recall encoded one a and/or are group vaccine.
Most to X study presented who within on patients, activity benefit.
Preliminary ESMO, with A Patients with data prior demonstrated designed single novo, demonstrated in X
Additionally, supporting our micrograms, tested the cancer dose showed durability which year. that also multiple responses B period selection confirmation of were successful sustained ongoing the of selected the patients of monitoring design. this began responses responding Part study, T-cell and At antigens, had dose August encoded of was dose XX enrollment of for T-cell antigen mRNA XX% against The highest in days. over XXX-microgram a XXX
The of half is first Part second XXXX. in of expected data readout the C
already I resected And oncology advanced Slide the path have Part XX, study in XX continue to enrollment That our is as mentioned. on the of glioblastoma the program catalyst, upcoming a most of advance which strong summarized dose our pipeline.
And next provides our well. We progressing months. confirmation oncology over development Phase B is off-the-shelf we
off-the-shelf provide be enrollment readout completed to to dosed II XXXX.
Data Phase patients first data a study, proprietary cancer antigen the with expect programs will non-small work enter in start XXX in continuing squamous allowing in in second in at our off-the-shelf disclose of Phase new in program could second half half half we XXXX. lung additional We potentially XXXX. of 'XX. development for the indications an clinical the The intend B of different clinical XXXX, basis additional latest of micrograms I for to newly expected cell second in announced half the the With discovery to candidates XX which is from Part the to up continuing,
expected in second a highlight Lastly, oncology, I mRNA personalized innovation XXXX. vaccine the in focus to candidate opportunities These the of start our strategic first with in leveraging cancer Phase catalysts our is to clinical technology our study oncology ensure half strong and pipeline. on designed continued progress
in and In gears vaccine UPEC indications fungi, respiratory UPEC uropathogenic in non-respiratory in owned bacteria, over Slide shift are to more towards the ongoing the common with our fully Targeting worldwide. high recurrent there caused practice. program with excited efforts options annually conventional this UTIs. GSK. high burden statistics presents costs reaching are patients the a now benefiting from infectious cost-effective our the of and technologies.
In need with amongst disease non-respiratory high to indications by and bacteria we of while me clinical U.S. infectious medical deliver increased disease current limited billions advantage of short very treatment mRNA tract to technology significant proprietary infections substantial This resistance the coli and licensed presented areas associated in of XX% we viruses development a research medical and leading primary Let introduce infections, offers with dollars disease of we recurrence The antibiotic which to urinary highlights medical diseases, to turn unmet in infectious The on the current alone.
Currently, area. UTIs antibiotic UPEC. therapy, new directing safe new of development is programs incidence compelling most requiring to U.S. challenge cause XX targeting E. and prevent aim prevalence potential rank vaccines our direct where results than market current an for area, rates infections are
UPEC. for developed this inducing tackle Our potential best-in-class To a as candidate deliver as FIH, solution, we adhesion technology observed has to represents highly a vaccine tissue target FIH and of considered the a infection, formation. responses in vast an including the patients. protein excellent encode bacteria is bladder therefore, UPEC's strain T-cell functional crucial the against mRNA bacterial majority and well to vaccine mRNA bias antibodies for function of
vaccine antigen candidates our we For to in studies, tested rational preclinical optimize immunogenicity. have applied designs
in even to that to a assembly a applied expected candidates In design of technology lead the to addition, cell unique SIH design higher This lead we have nanoparticle. innovative immunogenicity. vivo is to
X preclinical our at Slide the me On data with see serum the mice candidates vaccines. preclinical non-licensed currently promising models halogenation are functional created Trying can candidates. place week our to we measured with bacterial first and Let this and you Boston. meaning very Conference in in urine data, tested in models being We of the Health preclinical XXth mRNA in candidates. adhesion vaccine inhibiting which both X you direct in antibodies, comparison were taking of XX, binding show antibodies presented and/or recombinant and protein
Additionally, titers determined urine CDX high in T-cell serum. candidates functional with and both blood highly induced CDX responses of Both mice. models vaccine antibody in levels titers binding and mRNA correlated also that antibody in in were
compared were functional Importantly, serum higher the with candidates protein-based mRNA vaccines. to antibodies both comparator vaccine
antibody other of enduring Our tested nanoparticle serum highest candidate of all binding animals, in candidates. and FIMH the the functional demonstrated specific overall responses outperforming levels
based vaccines T-cell both XX. our Slide progress other on catalysts solid induced again responses candidate both disease show all programs with Additionally, than outlined strongly advancing protein-based and candidates infectious with promising candidates.
Overall, higher respiratory comparator the outperforming mRNA on nanoparticle vaccine areas non-respiratory development a
enabling the of development in submission half the select candidate UPEC program, clinical IND to file launched for to in to half of start first expect second a XXXX. clinical anticipated first newly of to in I XXXX, the our is allow half XXXX. This us For Phase we
work candidates the our which non-respiratory for diseases with XXXX in programs second Additional pipeline anticipate also in additional in other clinical is discovery XXXX. And progressing. of in selected this be strengthening we could half area
For the GSK. discretion time the the lines note the respiratory that remains disclosure of program licensed to please GSK, at of
avian I for the GSK, combination the a Data is recently initiate the found influenza a to study review XXXX. III for lines is influenza be this, the of is data. expected XXXX. Phase include in program information to about confirmed combined GSK study like COVID-XX the to readout new first to in over Corresponding on by data in to As Axel for an Phase the hand influenza Further of update portfolio time for I available anticipated clinicaltrials.gov. program progress also license first half half of vaccine. the can XXXX.
With expected and would conclude financial seasonal
